Universal childhood immunisation against Streptococcus pneumoniae: The five-year experience of Liguria Region, Italy

被引:57
作者
Durando, Paolo [1 ]
Crovari, Pietro
Ansaldi, Filippo
Sticchi, Laura
Sticchi, Camilla
Turello, Valter [2 ]
Marensi, Lorenzo [2 ]
Giacchino, Raffaella [3 ]
Timitilli, Anna [3 ]
Carloni, Roberto [4 ]
Azzari, Chiara [5 ]
Icardi, Giancarlo
机构
[1] Univ Genoa, San Martino Hosp, Sect Hyg & Prevent Med, Dept Hlth Sci, I-16132 Genoa, Italy
[2] Local Publ Hlth Unit Genoa ASL 3 Genovese, I-16121 Genoa, Italy
[3] IRCCS Gaslini, Infect Dis Unit, I-16147 Genoa, Italy
[4] Adm Reg Liguria, Dept Hlth & Social Serv, I-16121 Genoa, Italy
[5] Univ Florence, A Meyer Hosp, Dept Pediat, I-50132 Florence, Italy
关键词
Heptavalent pneumococcal conjugate vaccine (PCV-7); Immunogenicity; Pneumococcal-associated hospitalisations; PNEUMOCOCCAL CONJUGATE VACCINE; IMMUNOGENICITY; TOLERABILITY; SAFETY;
D O I
10.1016/j.vaccine.2009.01.052
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Liguria was the first Italian Administrative Region, since 2003, to actively recommend free-of-charge immunisation, of all infants, with heptavalent Pneumococcal Conjugate Vaccine (PCV-7), within a research pilot-project. Vaccination coverage among infants rapidly increased from 42.8% in 2003 to 83.3% in 2004, progressively reaching levels of 93.4% in 2007. Two scientific projects have been carried Out, aimed: (i) to assess the immunogenicity of PCV-7 and of a hexavalent vaccine Diphtheria-Tetanus-Trivalent Acellular Pertussis-Hepatitis B-Inactivated Polio Virus-Haemophilus influenzae type B (DTaP-HBV-IPV-Hib) when co-administered to healthy infants at 3,5 and 11-12 months of age (routine schedule), and (it) to evaluate the effect of the immunisation campaign in preventing Pneumococcal-associated hospitalisations. Results in 151 infants showed the high immunogenicity of the vaccines, seroprotection rates, Measured 1 month after the third dose, ranging between 97.3% (serotype 6 B) and 100% (serotypes 4 and 9 V) for PCV-7 and between 99.3% and 100% against common antigens of hexavalent vaccine. Monitoring nearly 70,000 children, aged 0-24 months, during the period 2000-2007, and comparing hospitalisation rates occurred in subjects belonging to birth cohorts before and after the introduction of widespread immunisation, a significant decline for all-cause and pneumococcal pneumonia and for acute otitis media was observed, with preventive fractions of 15.2%, 70.5% and 36.4%, respectively. (c) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3459 / 3462
页数:4
相关论文
共 11 条
[1]   Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children [J].
Black, S ;
Shinefield, H ;
Fireman, B ;
Lewis, E ;
Ray, P ;
Hansen, JR ;
Elvin, L ;
Ensor, KM ;
Hackell, J ;
Siber, G ;
Malinoski, F ;
Madore, D ;
Chang, I ;
Kohberger, R ;
Watson, W ;
Austrian, R ;
Edwards, K .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2000, 19 (03) :187-195
[2]   Immunogenicity, safety and tolerability of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months post-natally to pre- and full-term infants [J].
Esposito, S ;
Pugni, L ;
Bosis, S ;
Proto, A ;
Cesati, L ;
Bianchi, C ;
Cimino, C ;
Mosca, F ;
Principi, N .
VACCINE, 2005, 23 (14) :1703-1708
[3]   Brief review of the clinical effectiveness of PREVENAR® against otitis media [J].
Fletcher, Mark A. ;
Fritzell, Bernard .
VACCINE, 2007, 25 (13) :2507-2512
[4]   Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis [J].
Grijalva, Carlos G. ;
Nuorti, J. Pekka ;
Arbogast, Patrick G. ;
Martin, Stacey W. ;
Edwards, Kathryn M. ;
Griffin, Marie R. .
LANCET, 2007, 369 (9568) :1179-1186
[5]  
*IT MIN HLTH, NAT IMM PLAN 2005 20
[6]   Immunogenicity and tolerability of a heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 12 months of age [J].
Käyhty, H ;
Åhman, H ;
Eriksson, K ;
Sörberg, M ;
Nilsson, L .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2005, 24 (02) :108-114
[7]   Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa-HBV-IPV/Hib combination vaccine in healthy infants [J].
Knuf, M. ;
Habermehl, P. ;
Cimino, C. ;
Petersen, G. ;
Schmitt, H. -J. .
VACCINE, 2006, 24 (22) :4727-4736
[8]  
Shah S.S., 2006, CLIN INFECT DIS, V42, P1
[9]  
US Department of Health and Human Services. National Center for Health Statistics and the Centers for Medicare and Medicaid Services, INT CLASS DIS
[10]  
*WHO, 2005, TECHN REP SER, V927